Research ArticleExperimental Studies
Mifepristone Treatment Improves Length and Quality of Survival of Mice with Spontaneous Leukemia
JEROME H. CHECK, LYNN SANSOUCIE, JOSHUA CHERN, NKECHINYERE AMADI and YOUVAL KATZ
Anticancer Research August 2009, 29 (8) 2977-2980;
JEROME H. CHECK
LYNN SANSOUCIE
JOSHUA CHERN
NKECHINYERE AMADI
In this issue
Anticancer Research
Vol. 29, Issue 8
August 2009
Mifepristone Treatment Improves Length and Quality of Survival of Mice with Spontaneous Leukemia
JEROME H. CHECK, LYNN SANSOUCIE, JOSHUA CHERN, NKECHINYERE AMADI, YOUVAL KATZ
Anticancer Research Aug 2009, 29 (8) 2977-2980;
Jump to section
Related Articles
- No related articles found.
Cited By...
- New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor
- Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life
- Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers - A Review
- Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor
- Evidence that Mifepristone, a Progesterone Receptor Antagonist, Can Cross the Blood Brain Barrier and Provide Palliative Benefits for Glioblastoma Multiforme Grade IV
- Mifepristone Causing Complete Remission of Rapidly Advancing Leukemia with Measurement of Progesterone-induced Blocking Factor
- Progesterone Receptor Antagonist Therapy Has Therapeutic Potential Even in Cancer Restricted to Males as Evidenced from Murine Testicular and Prostate Cancer Studies
- Efficacy of the Progesterone Receptor Antagonist Mifepristone for Palliative Therapy of Patients with a Variety of Advanced Cancer Types